Search by Drug Name or NDC

NDC 55513-0164-01 Kanjinti Details

Kanjinti

Kanjinti is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amgen Inc. The primary component is .

MedlinePlus Drug Summary

Trastuzumab injection products are used with other medications or after other medications have been used to treat a certain type of breast cancer that has spread to other parts of the body. Trastuzumab injection products are also used during and after treatment with other medications to decrease the chance that a certain type of breast cancer will return. Trastuzumab injection products are also used with other medications to treat certain types of stomach cancer that have spread to other parts of the body. Trastuzumab is in a class of medications called monoclonal antibodies. It works by stopping the growth of cancer cells.

Related Packages: 55513-0164-01
Last Updated: 04/21/2024
MedLinePlus Full Drug Details: Trastuzumab Injection

Product Information

NDC	55513-0164
Product ID	55513-164_14829f5f-b04b-4479-bcfb-809fb1570ae7
Associated GPIs
GCN Sequence Number	079868
GCN Sequence Number Description	trastuzumab-anns VIAL 420 MG INTRAVEN
HIC3	V1W
HIC3 Description	ANTINEOPLASTIC EGF RECEPTOR BLOCKER MCLON ANTIBODY
GCN	46465
HICL Sequence Number	045796
HICL Sequence Number Description	TRASTUZUMAB-ANNS
Brand/Generic	Brand
Proprietary Name	Kanjinti
Proprietary Name Suffix	n/a
Non-Proprietary Name	trastuzumab-anns
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	KIT
Route	n/a
Active Ingredient Strength	n/a
Active Ingredient Units	n/a
Substance Name	n/a
Labeler Name	Amgen Inc
Pharmaceutical Class	n/a
DEA Schedule	n/a
Marketing Category	BLA
Application Number	BLA761073
Listing Certified Through	2024-12-31

Package

NDC 55513-0164-01 (55513016401)

Pricing Information	N/A
NDC Package Code	55513-164-01
Billing NDC	55513016401
Package	1 KIT in 1 CARTON (55513-164-01) * 20 mL in 1 VIAL, MULTI-DOSE (55513-132-02) * 20 mL in 1 VIAL (55513-152-01)
Marketing Start Date	2023-02-01
NDC Exclude Flag	N